Capital Increase / Dilution2026-07-21

CXI Healthcare plans 253.5M HKD capital increase

CXI

씨엑스아이

900120

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2589

Risk-adjusted indicator based on 2589 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Operating Funds: 253,538,981.63 HKD (approx. 47.9B KRW)
  • • Pre-increase Shares: 16,669,660 Shares (before 5:1 stock split)
  • • Stock Split Ratio: 5:1
  • • Share Par Value: 2.5 USD (approx. 3,710.75 KRW)
  • • Issuance Date: July 21, 2026

AI Analysis Summary

CXI Healthcare Technology Group Limited announced a decision for a paid-in capital increase to raise 253,538,981.63 HKD (approximately 47.9 billion KRW) for operating funds. The company, a foreign holding company listed on KOSDAQ with primary operations in China, faces restrictions on transferring funds from its Chinese subsidiaries. This capital increase aims to secure funds for parent company operations, investments, and to strengthen its financial health and going concern basis, following recent capital reduction and stock consolidation efforts. The issuance will be a third-party allocation, acknowledging potential dilution for existing shareholders, but management believes it will enhance long-term corporate and shareholder value. The plan is contingent on approval at an extraordinary general meeting on August 11, 2026.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.